+ Watch AGIO
on My Watchlist
near term oversold situation
Agios has been a fun stock this spring, maintaining high volatility despite the heavy smog crushing the biopharma sector. In April the stock spiked as high as 48 after the company reported several complete and incomplete remissions from a phase I trial of mutated IDH2 inhibitor AG-221. The stock couldn't maintain that level, withering under the onslaught of "just phase I data" naysayers. Of course, some stocks like Pharmacyclics pop on phase I data and never look back. Agios also has several other compounds in the clinic including the mutated IDH2 inhibitor AG-120 in phase I for both hematologic malignancies and advanced solid tumors, and RBC pyruvate kinase activator AG-348 in phase I for pyruvate kinase deficiency. The current market cap of a billion isn't exactly pocket change, nor is it extravagant for a biopharma with two independent proprietary platforms and a solid partnership with Celgene. The zzporte portfolio has 100 shares at 36 and may continue to build below 30.
will be taken out
I have 20 AGIO shares in my private (i.e. non-zzporte) portfolio.
rc - celg backed
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions